Precision Biosciences Inc (DTIL) 13F Filing Data & Analysis (Q2 2026)

DTIL ranks #4650 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

DTIL is a top-conviction position for Empery Asset Management, LP — at 7.0% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in DTIL belongs to Aberdeen Group plc, but the position matters far more to Empery Asset Management, LP, who has 7.0% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Bleichroeder LP has added to its DTIL position for two straight quarters, increasing it by $8.9M to reach $15.9M today.

Jim Simons has trimmed its DTIL position for two straight quarters, cutting it by $819.1K while still holding $539.0K.

DTIL is down 2.5% today, but institutions show net buying of $19.3M this quarter — a divergence between today's price move and the underlying institutional flow.

DTIL reported a net loss of $52.7M over the trailing twelve months.

• Not yet profitable — net loss of $52.7M over the trailing twelve months
• Revenue grew 3473.0% year over year
• Net income improved year over year, from -$78.3M to -$52.7M
• Operating cash flow was negative, using $65.8M in cash
• Current ratio of 13.32x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.67x equity — within a conventional range